Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2006 Oct 3;60(8):931–934. doi: 10.1136/jcp.2006.042242

A laboratory strategy for genotyping haemoglobin H disease in the Chinese

Amy Yuk‐Yin Chan 1,2, Chi‐Chiu So 1,2, Edmond Shiu‐Kwan Ma 1,2, Li‐Chong Chan
PMCID: PMC1994485  PMID: 17018682

Abstract

Background

The thalassaemias are the commonest blood disorders worldwide, with South East Asia and southern China as areas of high prevalence. Accurate diagnosis of these disorders helps in clinical management with improved outcome.

Methods

The α‐globin genotypes of 100 Chinese patients in Hong Kong with haemoglobin H (Hb H) disease were characterised. Single‐tube multiplex gap‐PCR was used to detect −−SEA, −α3.7 and −α4.2, while Hb CS, Hb QS and codon 30 (ΔGAG) were identified by single‐tube multiplex amplification refractory mutation system (ARMS). Automated direct nucleotide sequencing of the amplified α2‐ and α1‐globin genes was performed to characterise other non‐deletional α‐thalassaemia determinants.

Results

In the 100 cases studied, 99 cases had −−SEA in combination with deletional α+‐thalassaemia or non‐deletional α‐globin gene mutation involving the α2‐globin gene. In 70 cases of the deletional form, 43 cases showed the genotype of (−−SEA/−α3.7) and 27 cases of (−−SEA/−α4.2). Three of the 27 cases of (−−SEA/−α4.2) were found to have Hb Q‐Thailand linked in‐cis with −α4.2. The remaining 30 cases were of non‐deletional form with the following genotypes: 11 cases of (−−SEAHbCSα), 9 cases of (−−SEAHbQSα), 3 cases of (−−SEAcd30 (ΔGAG)α), 3 cases of (−−SEAcd31α), 2 cases of (−−SEApoly‐Aα), 1 case of (−−SEAHbWestmeadα) and 1 case of (−−non‐SEAHbQSα).

Conclusions

Based on two rapid diagnostic tests, multiplex gap‐PCR and multiplex ARMS, more than 90% of the cases were genetically characterised. This laboratory strategy should be widely applicable for genetic diagnosis of α‐thalassaemia.

Keywords: Hb H disease, α‐thalassemia mutations, multiplex gap‐PCR, multiplex ARMS, laboratory strategy


The α‐thalassaemia syndromes represent a common genetic disorder due to an absence or diminished synthesis of α globin chain of the haemoglobin (Hb) molecule. The human globin gene cluster is located on chromosome 16p13.3‐pter. This cluster contains three genes and four pseudogenes arranged as follows: 5′ ζ2‐ψζ1‐ψα2‐ψα1‐α2‐α1‐θ1 3′. α‐Thalassaemia frequently results from deletions of α‐globin genes. Non‐deletional mutations involving single to a few nucleotides within the structural genes account for a small proportion of cases.1,2

α‐Thalassaemia traits are caused by deletion or non‐deletional mutation of one (−α/αα, αTα/αα or ααT/αα) or two (−−/αα or −α/−α) α‐globin genes. Patients with Hb H disease show loss or inactivation of three α‐globin genes (−−/−α or −−/αTα or −−/ααT). They have a moderately severe haemolytic anaemia with a variable clinical course. In Hb Bart's hydrops fetalis (−−/−−), severe intrauterine anaemia develops that results in fetal death at or around the time of birth.1,3,4

Population studies have indicated that the types and frequencies of the different α‐thalassaemia defects vary among different ethnic groups.1 In Hong Kong, the commonest α°‐thalassaemia determinant is the South East Asian deletion (−−SEA) which removes nearly 20 kb DNA of the α‐globin gene cluster.5 The common α+‐thalassaemia determinants are the rightward deletion (−α3.7) and leftward deletion (−α4.2).5,6 The more common non‐deletional α2‐thalassaemia determinants include Hb Constant Spring (Hb CS), Hb Quong Sze (Hb QS) and codon 30 (ΔGAG).5,6 As Hb H disease follows a variable clinical course ranging from asymptomatic to multi‐organ morbidity, the latter more associated with non‐deletional forms, there is a rationale for early and accurate diagnosis of Hb H disease at the genotypic level prior to onset of complications. Improved patient care for patients with high risk Hb H disease may be achieved with laboratory and clinical monitoring. In this study, we present a rapid and simple laboratory approach for molecular diagnosis of Hb H disease.

Materials and methods

Patient samples

Between 1998 and 2003, 100 cases of Hb H disease (97 Chinese, 2 Thais, 1 Filipino) were diagnosed by routine haemoglobin study. Seven cases were related, coming from three families with Hb H disease. The age range was 1–84 years, with more than two‐thirds of the patients older than 20 years and one‐third older than 40 years.

DNA analysis

Genomic DNA was extracted from peripheral blood of patients. Multiplex gap‐PCR7 was adopted and modified to detect −−SEA, −α3.7 and −α4.2. Genomic DNA samples were amplified in a GeneAmp9700 thermocycler using the following cycling parameters: initial denaturation at 95°C for 15 min, followed by 30 cycles of 98°C denaturing for 45 s, 60°C annealing for 1 min 30 s, and 72°C extension 2 min 15 s. A final 5 min extension completed the reaction. Each PCR was set up in a total volume of 50 μl containing: 300–600 ng genomic DNA, 200 μM of each dNTP, 1.5 mM MgCl2, 1× Q‐solution (Qiagen, Hilden, Germany), 2.5 U HotStarTaq DNA polymerase in supplied reaction buffer (Qiagen) and 9 different primers at various concentrations (table 1). A 10 μl aliquot of each amplified product was analysed by electrophoresis on a 1% agarose gel after staining with ethidium bromide.

Table 1 Primer sequences for α‐thalassaemia multiplex gap‐PCR and multiplex amplification refractory mutation system (ARMS) assay.

Allele detected Name Primer sequences (5′ → 3′) Conc (μM) Fragment (bp)
α‐thalassaemia multiplex gap‐PCR
LIS 3′UTR fragment LIS1 (forward) ATACCATGGTTACCCCATTGAGC 0.5 2350
(internal control) LIS1 (reverse) AGGGCTCATTACATGTGGACCC 0.5
−α3.7 α2/3.7 (forward) CCCCTCGCCAAGTCCACCC 0.2 2022/2029
3.7 (reverse) AAAGCACTCTAGGGTCCAGCG 0.2
α2 gene α2/3.7 (forward) as above 1800
α2 (reverse) AGACCAGGAAGGGCCGGTG 0.2
−α4.2 4.2 (forward) GGTTTACCCATGTGGTGCCTC 0.5 1628
4.2 (reverse) CCCGTTGGATCTTCTCATTTCCC 0.5
−−SEA SEA (forward) CGATCTGGGCTCTGTGTTCTC 0.2 1349
SEA (reverse) AGCCCACGTTGTGTTCATGGC 0.2
α‐thalassaemia multiplex ARMS assay
ζ2‐globin gene fragment ENG12 (forward) GGATCCACGCAGTGCTAGAAG 0.294 930*
(internal control) ENG21 (reverse) GTAGAGATGGTGTTTTGCCATGT 0.294
codon 30 (ΔGAG) ARMSC30 (forward) GTATGGTGCGGAGGCCCTGAG 0.074 772
BE17 (reverse) CCATTGTTGGCACATTCCGGGA 0.140
codon 125 (CTG→CCG) ARMSC125 (forward) CACCCCTGCGGTGCACGCCTCACC 0.013 234
Hb Quong Sze BE17 (reverse) as above
Termination codon (TAA→CAA) ARMSC142 (forward) CCGTGCTGACCTCCAAATACGGTC 0.096 184
Hb Constant Spring BE17 (reverse) as above

*This fragment migrates at ∼1200 bp on non‐denaturing polyacrylamide gels.

For the detection of the three common non‐deletional α2‐thalassaemia determinants, Hb CS, Hb QS and codon 30 (ΔGAG), the multiplex amplification refractory mutation system (ARMS)8 approach was modified and used. Genomic DNA samples were amplified in a GeneAmp9700 thermocycler using the following cycling parameters: initial denaturation at 94°C for 12 min, followed by 32 cycles of 94°C denaturing for 40 s, 62°C annealing for 20 s, and 72°C extension 3 min. A final 7 minutes extension completed the reaction. Each PCR was set up in a total volume of 20 μl containing: 200 μM of each dNTP, 2.0 mM MgCl2, 10% dimethysulphoxide, 16.5 mM ammonium sulphate, 0.01% (w/v) gelatin, 10 mM Tris‐HCl, pH 8.3, 50 mM KCl, 5 U AmpliTaq Gold DNA polymerase and 6 different primers at various concentrations (table 1). A 10 μl aliquot of each amplified product was analysed by electrophoresis on a 8% non‐denaturing polyacrylamide gel after staining with ethidium bromide.

Automated direct nucleotide sequencing (ABI 377, Applied Biosystems, Foster City, California, USA) of the amplified α2‐ and α1‐globin genes was performed to characterise other non‐deletional α‐thalassaemia determinants.9

Results

Table 2 presents results of α genotyping for all cases. All except one were caused by co‐inheritance of −−SEA with either deletional or non‐deletional α+‐thalassaemia determinants. Deletional Hb H disease, that is −−SEA in association with α+‐deletion (−α3.7 and −α4.2), accounted for 70% of the cases. Figure 2 shows the electrophoretic results of multiplex gap‐PCR product in deletional Hb H disease on 1% agarose gel. Three cases of (−−SEA/−α4.2) were also found to have Hb Q‐Thailand10,11 linked in‐cis with −α4.2 by direct nucleotide sequencing of the amplified α1‐globin gene.

Table 2 α‐Globin genotypes of 100 patients with Hb H disease.

No
Deletional
(−−SEA/−α3.7) 43†
(−−SEA/−α4.2) 24
(−−SEA/−α4.2 Q‐Thailand [Codon 74 GAC→CAC or Asp→His]) 3
Subtotal: 70
Non‐deletional
(−−SEAConstant Spring [Codon 142 TAA→CAA or Term→Gln]α) 11
(−−SEAQuong Sze [Codon 125 CTG→CCG or Leu→Pro]α) 9
(−−SEACodon 30 deletion of GAGα) 3
(−−SEACodon 31 AGG→AAG or Arg→Lysα) 3‡
(−−SEAPoly‐A signal AATAAA→AATGAAα)
(−−SEAWestmead [Codon 122 CAC→CAG or His →Gln]α) 1
(−−Non‐SEAQuong Sze [Codon 125 CTG→CCG or Leu→Pro]α) 1
Subtotal: 30
Total: 100

*Two individuals had concomitant β‐thalassaemia trait (one −−SEA/−α3.7, one −−SEAQuong Szeα)

†Three are brother and sister.

‡Two are brother and sister.

§Two are brother and sister.

graphic file with name cp42242.f2.jpg

Figure 2 Electrophoretic results of multiplex gap PCR products on 1% agarose gel in deletional Hb H disease.

Among the remaining 30% of cases with Hb H disease, six different types of non‐deletional determinants were found, all in the α2‐globin gene. They were Hb CS, Hb QS, codon 30 (ΔGAG),12 codon 31 (AGG→AAG),13 poly‐A signal (AATAAA→AATGAA)14 and Hb Westmead (codon 122 CAC→CAG).14,15 Our multiplex ARMS detected Hb CS, Hb QS and codon 30 (ΔGAG) and resolved 80% (ie 24/30) of the non‐deletional cases. Figure 3 shows the electrophoretic results of three common non‐deletional Hb H disease as detected by our multiplex ARMS in an aqueous 8% polyacrylamide gel.

graphic file with name cp42242.f3.jpg

Figure 3 Electrophoretic results of multiplex amplification refractory mutation system products on aqueous 8% polyacrylamide gel in non‐deletional Hb H disease. Lane M is the 100 bp DNA size marker. The 930 bp internal control fragment migrates at ∼1200 bp on non‐denaturing polyacrylamide gel. Lanes 1, 2 and 6 are positive for Hb CS. Lane 3 is positive for codon 30 (ΔGAG). Lane 5 is positive for Hb QS. Lane 4 is negative for all of the three mutations. Only bands with greater intensity than the internal control fragment after ethidium bromide staining are regarded as positive.

The remaining three non‐deletional determinants were characterised by direct nucleotide sequencing of the amplified α2‐globin gene. They were codon 31 (AGG→AAG),13 poly‐A signal AATAAA→AATGAA14 and Hb Westmead (codon 122 CAC→CAG).14,15 Figure 4 illustrates the automated sequencing result of codon 31 (AGG→AAG).

graphic file with name cp42242.f4.jpg

Figure 4 Result of direct automated sequencing of the α2‐globin gene, showing AGG→AAG mutation at codon 31. The normal allele is absent since the patient harbours SEA deletion on the other chromosome 16.

Discussion

The clinical severity of Hb H disease is known to be variable. There is evidence to show a more severe phenotype with non‐deletional forms (−−/αTα) compared with deletional forms (−−/−α),3,4,16,17,18 which leads to the view that Hb H disease is not as benign a disorder as previously thought.18 Patients with non‐deletional forms of Hb H may have significant anaemia, iron overload and multi‐organ morbidity. An early and accurate diagnosis of Hb H disease is therefore warranted. Many methods for genetic diagnosis of α‐thalassaemia are currently in use, including Southern blot analysis, direct nucleotide sequencing and reverse dot‐blotting.19 However, these approaches are labour‐intensive and time‐consuming. With our diagnostic strategy (fig 1), more than 90% of Hb H disease in our population can be characterised by performing only two multiplex PCRs, and direct sequencing is needed in <10% of cases. With adaptation to detect prevalent α‐globin mutations in their localities, our approach should also be applicable in other South East Asian countries. This strategy can be further modified by including primers for the detection of the −−MED and −(α)20.5 double‐gene deletions and becomes applicable in the Mediterranean area.7 However, this strategy may be less applicable in places like Cambodia or Papua New Guinea where access to fluorescent dye chemistry sequencing is much more limited.

graphic file with name cp42242.f1.jpg

Figure 1 Strategy for genotypic diagnosis of Hb H disease by multiplex gap‐PCR, multiplex ARMS‐PCR and automated direct nucleotide sequencing of the amplified α2‐ and α1‐globin genes.

Take‐home messages

  • A total of 100 haemoglobin H (Hb H) disease patients in Hong Kong have been characterised at the DNA level.

  • Single‐tube multiplex gap‐PCR was used to detect −−SEA,−α3.7 and −α4.2, while Hb CS, Hb QS and codon 30 (ΔGAG) were identified by single‐tube multiplex amplification refractory mutation system (ARMS).

  • Automated direct nucleotide sequencing of the amplified α2‐ and α1‐globin genes was performed to characterise other non‐deletional α‐thalassaemia determinants.

  • Based on two rapid diagnostic tests, namely multiplex gap‐PCR and multiplex ARMS, >90% of the cases were genetically characterised.

  • This laboratory strategy should be widely applicable for genetic diagnosis of α‐thalassaemia.

Prenatal diagnosis for Hb H disease is not routinely performed as it is not generally regarded as a severe condition. Whether genetic risk prediction is indicated for a non‐fatal disorder that is associated with significant morbidity, such as Hb H disease, will have to be considered in light of recent evidence of more severe forms of the disease, such as Hb H hydrops.16 However, current antenatal thalassaemia screening does not usually identify couples at risk of Hb H disease because −α4.2 or −α3.7 heterozygous carrier state cannot be reliably detected by phenotypic tests. Hence genetic counselling will not be offered even if Hb H disease is included as a target for screening.

The availability of a simple and effective α‐thalassaemia genotyping strategy as proposed in the present study will greatly facilitate carrier detection and its potential use in antenatal screening, molecular characterisation of Hb H disease, genotype–phenotype correlation as well as longitudinal studies on the natural history of clearly defined deletional and non‐deletional Hb H disease.

Abbreviations

ARMS - amplification refractory mutation system

Hb - haemoglobin

Footnotes

Funding: This work was funded by CRCG grant 10204405 from the University of Hong Kong, and a research grant from Queen Mary Hospital (TRAS 02‐3 01/13/55).

Competing interests: None declared.

References

  • 1.Higgs D R, Vickers A O M, Wilkie I ‐ M.et al A review of the molecular genetics of the human α‐globin gene cluster. Blood 1989731081–1104. [PubMed] [Google Scholar]
  • 2.Liebhaber S A. Α‐Thalassemia. Hemoglobin 198913685–731. [DOI] [PubMed] [Google Scholar]
  • 3.Chen F E, Ooi C, Ha S Y.et al Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 2000343544–550. [DOI] [PubMed] [Google Scholar]
  • 4.Waye J S, Eng B, Patterson M.et al Hemoglobin H (Hb H) disease in Canada: molecular diagnosis and review of 116 cases. Am J Hematol 20016811–15. [DOI] [PubMed] [Google Scholar]
  • 5.Lau Y L, Chan L C, Chan Y Y.et al Prevalence and genotypes of α‐ and β‐thalassemia carriers in Hong Kong‐implications for population screening. N Engl J Med 19973361298–1301. [DOI] [PubMed] [Google Scholar]
  • 6.Chan L C, Ma S K, Chan A Y Y.et al Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80 fL in areas with high prevalence of thalassemia? J Clin Pathol 200154317–320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tan A S C, Quah T C, Low P S.et al A rapid and reliable 7‐deletion multiplex polymerase chain reaction assay for α‐thalassemia. Blood 200198250–251. [DOI] [PubMed] [Google Scholar]
  • 8.Eng B, Patterson M, Walker L.et al Detection of severe non‐deletional α‐thalassemia mutations using a single‐tube multiplex ARMS assay. Genet Test 20015327–329. [DOI] [PubMed] [Google Scholar]
  • 9.Dodé C, Rochette J, Krishnamorthy R. Locus assignment of human α globin mutations by selective amplification and direct sequencing. Br J Haematol 199076275–281. [DOI] [PubMed] [Google Scholar]
  • 10.Leung K F S, Au W Y, Chan A Y Y.et al Haemoglobin Q‐Thailand and hereditary spherocytosis in a Chinese family. Clin Lab Haem 20012353–55. [DOI] [PubMed] [Google Scholar]
  • 11.Leung K F S, Ma E S K, Chan A Y Y.et al Clinical phenotype of haemoglobin Q‐H disease. J Clin Pathol 20045781–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ma S K, Chan A Y Y, Chiu E K W.et al Haemoglobin H disease due to (−−SEA) α‐globin gene deletion and α2‐codon 30 (ΔGAG) mutation: a family study. Clin Lab Haem 200123325–327. [DOI] [PubMed] [Google Scholar]
  • 13.Zhao Y Z, Xu X M. α2CD31 AGG→AAG, Arg→Lys causing non‐deletional α‐thalassemia in a Chinese family with HbH disease. Haematologica 200186541–542. [PubMed] [Google Scholar]
  • 14.Ma E S K, Chow E Y D, Chan A Y Y.et al Interaction between (−−SEA) α‐thalassemia deletion and uncommon non‐deletional α‐globin gene mutations in Chinese patients. Haematologica 200186539–540. [PubMed] [Google Scholar]
  • 15.Jiang N H, Liang S, Wen X J.et al Hb Westmead: An α2‐globin gene mutation detected by polymerase chain reaction and stu I cleavage. Hemoglobin 199115291–295. [DOI] [PubMed] [Google Scholar]
  • 16.Chan V, Chan V W Y, Tang M.et al Molecular defects in Hb H hydrops fetalis. Br J Haematol 199796224–228. [DOI] [PubMed] [Google Scholar]
  • 17.Chui D H K, Waye J S. Hydrops fetalis caused by α‐thalassemia: an emerging health care problem. Blood 1998912213–2222. [PubMed] [Google Scholar]
  • 18.Chui D H K, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003101791–800. [DOI] [PubMed] [Google Scholar]
  • 19.Chan V, Yam I, Chen F E.et al A reverse dot‐blot method for rapid detection of non‐deletion α thalassemia. Br J Haematol 1999104513–515. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES